Company Filing History:
1 out of 4 
1 out of 47 Years Active: 2009
Title: **Innovative Contributions of Inventor Chris Pleiman**
Introduction
Chris Pleiman, an innovative inventor hailing from Holladay, UT, has made significant contributions to the field of medicinal chemistry. With a focus on developing compounds that can aid in the treatment of abnormal cell growth, his work has the potential to impact various clinical conditions.
Latest Patents
Pleiman holds a noteworthy patent titled "4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof." This patent discloses compounds that are effective as activators of caspases, which are crucial for programmed cell death, or apoptosis. The implications of these compounds are vast, especially for the treatment of diseases characterized by uncontrolled cellular growth, such as cancer.
Career Highlights
Throughout his career, Chris Pleiman has worked with esteemed companies in the biotechnology sector. Notable among these are Myriad Pharmaceuticals, Inc. and Cytovia, Inc., where he has applied his expertise in drug development and chemical synthesis. His role in these organizations reflects his commitment to advancing medical therapeutics through innovative research.
Collaborations
Collaboration has been a key aspect of Pleiman's career, allowing him to engage with other talented scientists. Notable collaborators include Sui Xiong Cai and Nilantha Sudath Sirisoma, who have contributed to the research and development processes alongside him. These partnerships have undoubtedly enriched his work and led to advancements in his innovative projects.
Conclusion
Chris Pleiman's dedication to developing new therapeutic compounds underscores the vital role of inventors in the field of medicine. His patent, along with his collaborative efforts, represents a significant step forward in addressing complex medical challenges related to abnormal cell proliferation. Through his innovative spirit and professional collaborations, Pleiman continues to pave the way for advancements in clinical treatments.